首页 | 本学科首页   官方微博 | 高级检索  
     


PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
Affiliation:1. School of Public Health, Nanchang University, 461 Ba Yi Avenue, Nanchang, Jiangxi 330006, China;2. Jiangxi Provincial Key Laboratory of Preventive Medicine, Nanchang University, 461 Ba Yi Avenue, Nanchang, Jiangxi 330006, China;3. Hubei Provincial Center for Disease Control and Prevention, 35 Zhuo Daoquan North Road, Wuhan, Hubei 430079, China;1. BioAnalytical Lab, Meso Scale Discovery, 1601 Research Blvd, Rockville, MD, USA;2. Orinin-BioSystems, LE-52, Lotus Road 4, CHD City, Karnal, Haryana 132 001, India;3. ICAR-Indian Veterinary Research Institute (IVRI), Regional Station, Palampur, Himachal Pradesh 176 061, India;4. Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700 032, India;5. Department of Biochemistry, Kakatiya Medical College, Warangal 506 007, Telangana, India;6. Department of Applied Biology, CSIR-Indian Institute of Technology, Uppal Road, Tarnaka, Hyderabad 500 007, India;1. School of Business, Maynooth University, Maynooth, Co Kildare, Ireland;2. Alliance Management, Business Development, Licensing and Strategy (BDL&S), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden;3. Faculty Office and International Relations, Karolinska Institutet, Stockholm, Sweden;4. Global Corporate Affairs, AstraZeneca, Stockholm, Sweden;5. Department of Economy & Society, University of Gothenburg, Gothenburg, Sweden;6. Gothenburg U-GOT KIES Centre, University of Gothenburg, Gothenburg, Sweden
Abstract:
Keywords:ovarian cancer  immune checkpoint inhibitors  PD-1/PD-L1 blockade  drug resistance
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号